Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

— LAM-RFA  

Official title:

Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00555334
• Other study ID #: RFA-002
• Status: Recruiting
• Phase: Phase 4
• First received: November 7, 2007
• Last updated: March 31, 2009
• Start date: November 2007
• Est. completion date: December 2010

Study information

• Verified date: March 2009
• Source: Sun Yat-sen University
• Contact: Min-Shan Chen, Docter
• Phone: 86-20-87343117
• Email: Chminsh[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Health authority: China: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of the investigators' study is to prospectively evaluate whether nucleoid antiviral therapy will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 2010
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Inclusion Criteria:

• Age 18 - 75 years, who refused surgery;

• A solitary HCC = 7.0cm in diameter, or multiple HCC = 3 lesions, each = 3.0cm in diameter

• Lesions being visible on ultrasound (US) and with an acceptable/safe path between the lesion and the skin as shown on US,

• No extrahepatic metastasis

• No imaging evidence of invasion into the major portal/hepatic vein branches

• No history of encephalopathy, ascites refractory to diuretics or variceal bleeding

• A platelet count of > 40,000/mm3

• No previous treatment of HCC except liver resection.

Exclusion Criteria:

• Patient compliance is poor

• The blood supply of tumor lesions is absolutely poor or arterial-venous shunt that TACE can not be performed

• Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1). Any cancer curatively treated > 3 years prior to entry is permitted.

• History of cardiac disease:

• congestive heart failure > New York Heart Association (NYHA) class 2;

• active coronary artery disease (myocardial infarction more than 6 months prior to study entry is permitted);

• cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers, calcium channel blocker or digoxin; or

• uncontrolled hypertension (failure of diastolic blood pressure to fall below 90 mmHg, despite the use of 3 antihypertensive drugs).

• Active clinically serious infections (> grade 2 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)

• Known history of human immunodeficiency virus (HIV) infection

• Known Central Nervous System tumors including metastatic brain disease

• Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry

• Distantly extrahepatic metastasis

• History of organ allograft

• Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results

• Known or suspected allergy to the investigational agent or any agent given in association with this trial

• Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study

• Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.

• Excluded therapies and medications, previous and concomitant:

• Prior use of any systemic anti-cancer treatment for HCC, eg. chemotherapy, immunotherapy or hormonal therapy (except that hormonal therapy for supportive care is permitted). Antiviral treatment is allowed, however interferon therapy must be stopped at least 4 weeks prior randomization.

• Prior use of systemic investigational agents for HCC

• Autologous bone marrow transplant or stem cell rescue within four months of start of study drug

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma
• Liver Cancer
• Liver Neoplasms

Intervention

Procedure:
• RFA
radiofrequency ablation

Drug:
• lamivudine or entecavir
lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA

Locations

Country	Name	City	State
China	Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

References & Publications (4)

Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36. — View Citation

Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol. 2001;11(6):914-21. — View Citation

Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8. — View Citation

Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg. 2002 Apr;235(4):466-86. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survivals		3, 5-years	Yes
Secondary	Recurrence rates		3, 5-years	Yes